Collectively, this study demonstrates that the novel KDM1A-METTL3/IGF2BP1-STUB1 pathway enhances autophagy-mediated clearance of p-Tau accumulation and thus ameliorates AD, which supports METTL3 as a potential therapeutic target for AD (Figure 2). This evidence concerns the gene MAPT and Alzheimer disease.